Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Pres & Chief Operating Officer | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 191,729 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 17,562 · Balance 198,640 Row 2 · 2026-10-01 · Tax withholding · Disposed 6,911 · Balance 191,729 F1: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 17,563 |
Reported balance
After 2026-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Disposed 17,562 · Balance 17,563 F2: On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. F3: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,783 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 3,783 F6: On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F3: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,443 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 8,443 F10: On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F3: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,939 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 11,939 F13: On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F3: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 59,382 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 59,382 F3: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 152,594 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 152,594 F20: On March 1, 2026, Mr. Stone was granted 152,594 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F3: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2029-12-01 | Direct | 166,113 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 166,113 F4: On December 1, 2022, Mr. Stone was granted 166,113 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.65 · Expires 2030-05-11 | Direct | 53,969 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 53,969 F5: On May 11, 2023, Mr. Stone was granted 53,969 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 21,204 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 21,204 F7: On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F3: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 25,330 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 25,330 F9: On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F3: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 17,908 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 17,908 F12: On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F3: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2034-02-23 | Direct | 42,344 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 42,344 F8: On February 23, 2024, Mr. Stone was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.96 · Expires 2034-05-02 | Direct | 29,976 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 29,976 F11: On May 2, 2024, Mr. Stone was granted 29,976 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2035-02-21 | Direct | 143,266 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 143,266 F14: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. F15: On February 21, 2025, Mr. Stone was granted 143,266 stock options. At the time of the grant, the options vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone's promotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these options was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2035-04-01 | Direct | 94,518 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 94,518 F16: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%. F17: On April 1, 2025, Mr. Stone was granted 94,518 stock options. The options vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2036-03-01 | Direct | 253,378 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 253,378 F18: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 multiplied by 110%. F19: On March 1, 2026, Mr. Stone was granted 253,378 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
F2: On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
F3: Once vested, the shares of common stock are not subject to expiration.
F4: On December 1, 2022, Mr. Stone was granted 166,113 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F5: On May 11, 2023, Mr. Stone was granted 53,969 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F6: On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F7: On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
F8: On February 23, 2024, Mr. Stone was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F9: On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
F10: On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F11: On May 2, 2024, Mr. Stone was granted 29,976 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F12: On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
F13: On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F14: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
F15: On February 21, 2025, Mr. Stone was granted 143,266 stock options. At the time of the grant, the options vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone's promotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these options was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
F16: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
F17: On April 1, 2025, Mr. Stone was granted 94,518 stock options. The options vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
F18: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 multiplied by 110%.
F19: On March 1, 2026, Mr. Stone was granted 253,378 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F20: On March 1, 2026, Mr. Stone was granted 152,594 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 17,562 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-064959 · wk-form4_1791232140.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,563 Underlying: Common Stock · 17,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. F3 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 6,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-064959 · wk-form4_1791232140.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,729 F1 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 17,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-064959 · wk-form4_1791232140.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:33 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 28,106 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-058913 · wk-form4_1787689984.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,106 Underlying: Common Stock · 28,106 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On February 21, 2025, Mr. Stone was granted 84,317 restricted stock units. At the time of the grant, the restricted stock units vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone's promotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these restricted stock units was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:33 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 11,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-058913 · wk-form4_1787689984.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,078 Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:33 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 28,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-058913 · wk-form4_1787689984.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 5,830 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-034619 · wk-form4_1778703533.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,783 Underlying: Common Stock · 5,830 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 3,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-034619 · wk-form4_1778703533.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,032 Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 5,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-034619 · wk-form4_1778703533.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2026 Filed May 5, 2026 20:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 5,969 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-030619 · wk-form4_1778012808.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,939 Underlying: Common Stock · 5,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 02, 2026 Filed May 5, 2026 20:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,349 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-030619 · wk-form4_1778012808.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,985 F3 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| May 02, 2026 Filed May 5, 2026 20:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 5,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-030619 · wk-form4_1778012808.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the release of restricted stock units that were previously reported on a Form 4. F2 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics, Inc. common stock and is converted into common stock upon vesting. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 17,562 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023691 · wk-form4_1775248747.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,125 Underlying: Common Stock · 17,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 6,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023691 · wk-form4_1775248747.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,365 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 17,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023691 · wk-form4_1775248747.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 152,594 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014147 · wk-form4_1772579762.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,594 Underlying: Common Stock · 152,594 shares Expires not disclosed F3 · derivative.exercise_date: On March 1, 2026, Mr. Stone was granted 152,594 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 253,378 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001628280-26-014147 · wk-form4_1772579762.xml · derivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,378 Underlying: Common Stock · 253,378 shares Expires 2036-03-01 F1 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 multiplied by 110%. F2 · derivative.exercise_date: On March 1, 2026, Mr. Stone was granted 253,378 stock options. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 8,443 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011102 · wk-form4_1771967722.xml · derivative · entry 6 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,443 Underlying: Common Stock · 8,443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 3,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011102 · wk-form4_1771967722.xml · nonDerivative · entry 4 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,714 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011102 · wk-form4_1771967722.xml · nonDerivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| February 21, 2026 Filed Feb 24, 2026 21:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 28,105 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011102 · wk-form4_1771967722.xml · derivative · entry 5 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,212 Underlying: Common Stock · 28,105 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 21, 2025, Mr. Stone was granted 84,317 restricted stock units. At the time of the grant, the restricted stock units vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone'spromotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these restricted stock units was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grantdate. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 21, 2026 Filed Feb 24, 2026 21:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 7,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011102 · wk-form4_1771967722.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,594 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| February 21, 2026 Filed Feb 24, 2026 21:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 28,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011102 · wk-form4_1771967722.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 02:01 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 22,128 | $12.50 | $276,681.87 |
DisclosureSEC source: 0001628280-26-002970 · wk-form4_1769047301.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,631 Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 15,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002199 · wk-form4_1768512161.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,759 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 59,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002199 · wk-form4_1768512161.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 8,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-055121 · wk-form4_1764800230.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,504 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2025 vesting of restricted stock. Read SEC document |
| May 12, 2025 Filed May 13, 2025 20:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | PurchaseCommon Stock | 5,700 | $8.58 | $48,894.60 |
DisclosureSEC source: 0001077183-25-000104 · wk-form4_1747166720.xml · nonDerivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,280 Read SEC document |
| May 11, 2025 Filed May 13, 2025 20:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 9,613 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000104 · wk-form4_1747166720.xml · derivative · entry 4 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,613 Underlying: Common Stock · 9,613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2025 Filed May 13, 2025 20:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000104 · wk-form4_1747166720.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,580 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| May 11, 2025 Filed May 13, 2025 20:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 9,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000104 · wk-form4_1747166720.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000088 · wk-form4_1746562014.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,308 F3 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 5,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000088 · wk-form4_1746562014.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the release of restricted stock units that were previously reported on a Form 4. F2 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics, Inc. common stock and is converted into common stock upon vesting. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 52,687 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000059 · wk-form4_1743710846.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,687 Underlying: Common Stock · 52,687 shares Expires not disclosed F3 · derivative.exercise_date: On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. These restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 94,518 | $0.00 Strike: $10.44 | $0.00 |
DisclosureSEC source: 0001077183-25-000059 · wk-form4_1743710846.xml · derivative · entry 2 Stone Warren · CIK 0001955295 · Pres & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,518 Underlying: Common Stock · 94,518 shares Expires 2035-04-01 F1 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%. F2 · derivative.exercise_date: On April 1, 2025, Mr. Stone was granted 94,518 stock options. These options vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 8,443 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000041 · wk-form4_1740519572.xml · derivative · entry 5 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,886 Underlying: Common Stock · 8,443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000041 · wk-form4_1740519572.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,793 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000041 · wk-form4_1740519572.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 84,317 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000041 · wk-form4_1740519572.xml · derivative · entry 4 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,317 Underlying: Common Stock · 84,317 shares Expires not disclosed F5 · derivative.exercise_date: On February 21, 2025, Mr. Stone was granted 84,317 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 143,266 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001077183-25-000041 · wk-form4_1740519572.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,266 Underlying: Common Stock · 143,266 shares Expires 2035-02-21 F3 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. F4 · derivative.exercise_date: On February 21, 2025, Mr. Stone was granted 143,266 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 21:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 59,382 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000013 · wk-form4_1737061657.xml · derivative · entry 2 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,382 Underlying: Common Stock · 59,382 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| December 01, 2024 Filed Dec 4, 2024 02:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 6,224 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000167 · wk-form4_1733279420.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,822 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2024 vesting of restricted stock. F2 · balance_after: On May 14, 2024, the reporting person filed a Form 4 which inadvertently reported the number of shares of common stock received upon the vesting of certain of his RSUs twice. In fact, as reported on this Form 4, the reporting person directly owned 91,046 shares of common stock after the vesting of 9,612 RSUs and reported withholding. Column 5 of Table I on this Form 4 now includes the correct number of shares received upon such May 14, 2024 vesting. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 9,612 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000073 · wk-form4_1715737110.xml · derivative · entry 4 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,226 Underlying: Common Stock · 9,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 9,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000073 · wk-form4_1715737110.xml · nonDerivative · entry 3 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,341 | $14.86 | $34,787.26 |
DisclosureSEC source: 0001077183-24-000073 · wk-form4_1715737110.xml · nonDerivative · entry 2 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,046 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 9,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000073 · wk-form4_1715737110.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 17,908 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000062 · wk-form4_1714767046.xml · derivative · entry 11 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,908 Underlying: Common Stock · 17,908 shares Expires not disclosed F11 · derivative.exercise_date: On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 17,908 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000062 · wk-form4_1714767046.xml · derivative · entry 10 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,908 Underlying: Common Stock · 17,908 shares Expires not disclosed F10 · derivative.exercise_date: On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 29,976 | $0.00 Strike: $13.96 | $0.00 |
DisclosureSEC source: 0001077183-24-000062 · wk-form4_1714767046.xml · derivative · entry 9 Stone Warren · CIK 0001955295 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,976 Underlying: Common Stock · 29,976 shares Expires 2034-05-02 F9 · derivative.exercise_date: On May 2, 2024, Mr. Stone was granted 29,976 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 25,330 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000031 · wk-form4_1709069363.xml · derivative · entry 8 Stone Warren · CIK 0001955295 · President, Clinical Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,330 Underlying: Common Stock · 25,330 shares Expires not disclosed F8 · derivative.exercise_date: On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.